Literature DB >> 21211528

Successful methylphenidate treatment of early onset extreme obesity in a child with a melanocortin-4 receptor gene mutation and attention deficit/hyperactivity disorder.

Ozgür Albayrak1, Beate Albrecht, Susann Scherag, Nikolaus Barth, Anke Hinney, Johannes Hebebrand.   

Abstract

We present the case report of a 2 year old boy with early onset extreme obesity (body mass index (BMI) 34.2 kg/m²; body mass index standard deviation score (BMI-SDS) 5.4) who is heterozygous for a non-conservative functionally relevant melanocortin MC(4)receptor mutation (Glu308Lys) and who also showed severe symptoms of attention deficit/hyperactivity disorder (ADHD). Treatment with the stimulant methylphenidate led to a sharp decrease of BMI to 21.8 kg/m² (BMI-SDS 2.8) within 24 months. We discuss potential mechanisms for this unusually large weight loss and suggest a potential link between the melanocortinergic and the dopaminergic systems, and the sympathetic nervous system. The potential benefit of methylphenidate in obese melanocortin MC(4)receptor mutation carriers with and without co-morbid ADHD warrants further studies.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21211528     DOI: 10.1016/j.ejphar.2010.12.023

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

Review 1.  Synaptic changes induced by melanocortin signalling.

Authors:  Vanni Caruso; Malin C Lagerström; Pawel K Olszewski; Robert Fredriksson; Helgi B Schiöth
Journal:  Nat Rev Neurosci       Date:  2014-02       Impact factor: 34.870

Review 2.  Molecular genetic aspects of weight regulation.

Authors:  Johannes Hebebrand; Anke Hinney; Nadja Knoll; Anna-Lena Volckmar; André Scherag
Journal:  Dtsch Arztebl Int       Date:  2013-05-10       Impact factor: 5.594

3.  Obesity in men with childhood ADHD: a 33-year controlled, prospective, follow-up study.

Authors:  Samuele Cortese; Maria A Ramos Olazagasti; Rachel G Klein; F Xavier Castellanos; Erika Proal; Salvatore Mannuzza
Journal:  Pediatrics       Date:  2013-05-20       Impact factor: 7.124

4.  Obesity-associated melanocortin-4 receptor mutations are associated with changes in the brain response to food cues.

Authors:  Agatha A van der Klaauw; Elisabeth A H von dem Hagen; Julia M Keogh; Elana Henning; Stephen O'Rahilly; Andrew D Lawrence; Andrew J Calder; I Sadaf Farooqi
Journal:  J Clin Endocrinol Metab       Date:  2014-07-25       Impact factor: 5.958

5.  Dextroamphetamine Treatment in Children With Hypothalamic Obesity.

Authors:  Jiska van Schaik; Mila S Welling; Corjan J de Groot; Judith P van Eck; Alicia Juriaans; Marcella Burghard; Sebastianus B J Oude Ophuis; Boudewijn Bakker; Wim J E Tissing; Antoinette Y N Schouten-van Meeteren; Erica L T van den Akker; Hanneke M van Santen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-09       Impact factor: 5.555

6.  Successful treatment with atomoxetine of an adolescent boy with attention deficit/hyperactivity disorder, extreme obesity, and reduced melanocortin 4 receptor function.

Authors:  Wilfried Pott; Ozgür Albayrak; Anke Hinney; Johannes Hebebrand; Ursula Pauli-Pott
Journal:  Obes Facts       Date:  2013-03-06       Impact factor: 3.942

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.